Luminex partners with Abbott for newly cleared xTAG RVP test
This article was originally published in Clinica
Biological testing specialist Luminex has struck a deal with Abbott's molecular diagnostic business for the worldwide distribution of the former's xTAG respiratory viral panel (RVP). The deal, of which financial details were not revealed, will see Abbott gain semi-exclusive distribution rights to the product in the US, and exclusive rights for non-US markets. The xTAG RVP is based on Luminex's xMAP multiplexing technology and, according to the Austin, Texas-based company, can simultaneously test for twelve viruses and viral subtypes within a few hours after a patient sample is taken. The xTAG received 510(k) clearance from the US FDA in January 2008 (see Clinica No 1289, p 18).